Sign in

Matrix Capital Management Company, LP

CIK:0001410830
Hedge Fund
$5B AUM
4 holdings
Waltham, MA, USA
Founded:1999
16 employees
Latest filing:Jun 30, 2025

Matrix Capital Management Company, LP is a hedge fund founded in 1999 by David E. Goel and Paul J. Ferri. Headquartered in Waltham, Massachusetts, it operates as a Delaware limited partnership and serves institutional investors and high-net-worth individuals. The firm manages concentrated long/short equity portfolios and focuses on growth-oriented investments, particularly in technology and life sciences. As of 2025, it employs approximately 16 staff.

Investment Strategy

Matrix Capital Management pursues a fundamental, research-driven, long/short equity strategy, emphasizing deep dive analysis and a concentrated portfolio structure. The firm's approach favors growth sectors, especially technology and healthcare, identifying companies with significant disruptive potential. The philosophy centers on high conviction positions, rigorous due diligence, and a long-term investment horizon, while using short positions primarily for risk management rather than alpha generation.

Top Buys
G
GFSGLOBALFOUNDRIES INC
-$124.3M
Z
ZNTLZENTALIS PHARMACEUTICALS INC
-$6.0M
M
MAZEMAZE THERAPEUTICS INC
+$3.1M
A
AURAAURA BIOSCIENCES INC
+$2.8M
Top Sells
G
GFSGLOBALFOUNDRIES INC
-$124.3M
Z
ZNTLZENTALIS PHARMACEUTICALS INC
-$6.0M
M
MAZEMAZE THERAPEUTICS INC
+$3.1M
A
AURAAURA BIOSCIENCES INC
+$2.8M

Top Holdings

G
GFSGLOBALFOUNDRIES INC
+59.6%$132.7M
A
AURAAURA BIOSCIENCES INC
+19.5%$43.3M
M
MAZEMAZE THERAPEUTICS INC
+13.7%$30.5M
Z
ZNTLZENTALIS PHARMACEUTICALS INC
+7.3%$16.2M

Equity Positions (4)

TickerSecurityWeightMarket ValueSharesAvg CostPriceChange (QoQ)
G
GFS
GLOBALFOUNDRIES INC59.59%$132.7M3,475,000$54.35$38.20-$124.3M
A
AURA
AURA BIOSCIENCES INC19.45%$43.3M6,922,870$13.98$6.26+$2.8M
M
MAZE
MAZE THERAPEUTICS INC13.69%$30.5M2,486,184$11.01$12.27+$3.1M
Z
ZNTL
ZENTALIS PHARMACEUTICALS INC7.27%$16.2M13,959,973$34.78$1.16-$6.0M

Industry Allocation

SEMICONDUCTORS & RELATED DEVICES
+59.6%
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
+33.1%
PHARMACEUTICAL PREPARATIONS
+7.3%